AU2001272262A1 - Drug delivery system for poorly water soluble drugs - Google Patents

Drug delivery system for poorly water soluble drugs

Info

Publication number
AU2001272262A1
AU2001272262A1 AU2001272262A AU7226201A AU2001272262A1 AU 2001272262 A1 AU2001272262 A1 AU 2001272262A1 AU 2001272262 A AU2001272262 A AU 2001272262A AU 7226201 A AU7226201 A AU 7226201A AU 2001272262 A1 AU2001272262 A1 AU 2001272262A1
Authority
AU
Australia
Prior art keywords
chitosan
drug
hydrogel
water soluble
poorly water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272262A
Other languages
English (en)
Inventor
Esteban Chornet
Severian Dumitriu
Claudia Ishizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemestrie Inc
Original Assignee
Kemestrie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemestrie Inc filed Critical Kemestrie Inc
Publication of AU2001272262A1 publication Critical patent/AU2001272262A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Colloid Chemistry (AREA)
AU2001272262A 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs Abandoned AU2001272262A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21662700P 2000-07-07 2000-07-07
US60216627 2000-07-07
US25238900P 2000-11-21 2000-11-21
US60252389 2000-11-21
PCT/CA2001/000993 WO2002003962A2 (en) 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs

Publications (1)

Publication Number Publication Date
AU2001272262A1 true AU2001272262A1 (en) 2002-01-21

Family

ID=26911183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272262A Abandoned AU2001272262A1 (en) 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs

Country Status (12)

Country Link
US (1) US20030157171A1 (ja)
EP (1) EP1299089B1 (ja)
JP (1) JP2004502722A (ja)
AT (1) ATE322891T1 (ja)
AU (1) AU2001272262A1 (ja)
BR (1) BR0112258A (ja)
CA (1) CA2415081A1 (ja)
DE (1) DE60118742D1 (ja)
IL (1) IL153814A0 (ja)
NO (1) NO20030073L (ja)
NZ (1) NZ523418A (ja)
WO (1) WO2002003962A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062041A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pharmaceutical dissolution testing using a non-ionic surfactant
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
AU2006296991A1 (en) * 2005-09-28 2007-04-05 Dnp Canada Inc. Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2007117590A2 (en) 2006-04-05 2007-10-18 Woodland Biofuels Inc. System and method for converting biomass to ethanol via syngas
US20100129423A1 (en) * 2007-04-19 2010-05-27 Medovent Gmbh Device made at least partially of n-acetylchitosan with controlled biodissolution
CA2810842C (en) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
WO2013018050A2 (en) 2011-08-01 2013-02-07 Ranbaxy Laboratories Limited Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
CN103315960A (zh) * 2012-03-19 2013-09-25 胡容峰 基于球晶技术固体自微乳及其制备方法
US20200262937A1 (en) * 2017-09-27 2020-08-20 Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies (A4Tec)- High molecular weight chitosan, process for obtaining and uses thereof
KR102407470B1 (ko) * 2021-08-09 2022-06-10 인제대학교 산학협력단 하이드로겔에 담지된 약물의 방출량 검출 방법
CN114515268B (zh) * 2022-02-21 2024-06-21 上海宣泰医药科技股份有限公司 熊去氧胆酸药物组合物及其制备方法和药物制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620706A (en) * 1995-04-10 1997-04-15 Universite De Sherbrooke Polyionic insoluble hydrogels comprising xanthan and chitosan
CA2243619A1 (fr) * 1998-07-17 2000-01-17 Universite De Sherbrooke Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines

Also Published As

Publication number Publication date
ATE322891T1 (de) 2006-04-15
JP2004502722A (ja) 2004-01-29
DE60118742D1 (de) 2006-05-24
BR0112258A (pt) 2003-06-24
IL153814A0 (en) 2003-07-31
CA2415081A1 (en) 2002-01-17
NO20030073L (no) 2003-03-06
US20030157171A1 (en) 2003-08-21
WO2002003962A3 (en) 2002-06-13
EP1299089A2 (en) 2003-04-09
WO2002003962A2 (en) 2002-01-17
NO20030073D0 (no) 2003-01-07
NZ523418A (en) 2004-09-24
EP1299089B1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
Shah et al. Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs
Shu et al. Controlled drug release properties of ionically cross-linked chitosan beads: the influence of anion structure
CA2666587C (en) Micellar nanoparticles of chemical substances
EP1299089B1 (en) Drug delivery system for poorly water soluble drugs
Ganesan et al. Development, characterization and solubility enhancement of comparative dissolution study of second generation of solid dispersions and microspheres for poorly water soluble drug
JP2005517690A (ja) 固体薬物分散物を含有する即時放出剤形
JP2007504266A (ja) ジプラシドンの持続放出剤形
JPH11507958A (ja) 徐放性ヘテロ分散ヒドロゲル系―非晶薬物
CN101702878A (zh) 可溶性差的药物的药物组合物
Ivanova et al. In vitro and ex vivo studies on diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment
US20020076444A1 (en) Novel method for obtaining microspheres and resulting products
Segale et al. Calcium alginate multi-unit oral dosage form for delayed release of celecoxib
CN106511348A (zh) 石杉碱甲骨架微粒、口崩片及其制备方法
Ramana Preparation and In-vitro characterization of ethylcellulose coated pectin alginate microspheres of 5-fluorouracil for colon targeting
Krueger et al. “MCC SANAQ® burst”—a new type of cellulose and its suitability to prepare fast disintegrating pellets
MX2007002375A (es) Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad.
JP2002517431A (ja) マイクロ浸透圧制御薬物送達システム
Pi et al. Polymer blends used to develop felodipine-loaded hollow microspheres for improved oral bioavailability
TWI392507B (zh) 包埋的膠束奈米顆粒
Prado et al. Basic butylated methacrylate copolymer/kappa-carrageenan interpolyelectrolyte complex: preparation, characterization and drug release behaviour
Kunasekaran et al. Kinetic modeling of Rasagiline mesylate from nanoscale solid lipid particles
Atneriya et al. In vitro profiling of fenofibrate solid dispersion mediated tablet formulation to treat high blood cholesterol
JP3007387B2 (ja) 徐放性製剤用基剤粉末
Wang et al. Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice
KR100222306B1 (ko) 닐바디핀 속효성 고형제제 및 이의 제조방법

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application